glycosylation pathway. This type of glycosylation substantially alters the mass and net 23 charge of HIV envelope (Env) proteins compared to molecules with the same amino 24 acid sequence but possessing mature, complex (sialic acid containing) carbohydrates. 25
Since cell lines suitable for biopharmaceutical production that limit N-linked 26 glycosylation to mannose-5 (Man5) or earlier intermediates are not readily available, the 27 production of vaccine immunogens displaying these glycan dependent epitopes has 28 been challenging. Here we report the development of a stable suspension adapted 29 CHO cell line that limits glycosylation to Man5 and earlier intermediates. This cell line 30 was created using the CRISPR/Cas9 gene editing system and contains a mutation that 31 inactivates the gene encoding Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,2-N-32 Acetylglucosaminyltransferase (MGAT1). Monomeric gp120s produced in the MGAT1 -33 CHO cell line exhibit improved binding to prototypic glycan dependent bN-mAbs 34 directed to the V1/V2 domain (e.g. PG9) and the V3 stem (e.g. PGT128 and 10-1074) 35
while preserving the structure of the important glycan independent epitopes (e.g. 36 VRC01). The ability of the MGAT1-CHO cell line to limit glycosylation to early 37 intermediates in the N-linked glycosylation pathway, without impairing the doubling time 38 Introduction 42 Despite thirty years of research, a vaccine capable of providing protection 43 against human immunodeficiency virus type 1 (HIV) has yet to be described. However, 44 considerable progress towards this goal has been achieved with the elucidation of the 45 3-dimensional structure of the HIV-1 envelope proteins (monomeric gp120 and trimeric 46 gp140) and the characterization of multiple broadly neutralizing monoclonal antibodies 47 (bN-mAbs) (1-5). As headway toward a protective vaccine continues, the practicalities 48 of large-scale vaccine production must be addressed. A growing body of evidence 49
indicates that the N-linked glycosylation structure will be a critical factor in both the 50 design and manufacture of any HIV vaccine (6) (7) (8) . 51
Beginning in 2009, we learned that multiple bN-mAbs recognized glycan 52 dependent epitopes on the HIV envelope protein, gp120. In an unanticipated 53 development, several families of bN-mAbs require mannose-5 (Man5) and/or mannose-9 54 (Man9) for binding to key epitopes of gp120 (6, (9) (10) (11) . As these bN-mAbs were being 55 described, the data from the RV144 HIV vaccine trial was released. This study provided 56 evidence for the first time that vaccination could prevent HIV infection in humans (12) . 57
The regimen used in this trial involved immunization with a bivalent gp120 vaccine 58 (AIDSVAX B/E) to stimulate an antibody response as well as immunization with a 59 recombinant canarypox vector to stimulate a cell mediated immune response (13) (14) (15) . 60
This immunization protocol resulted in modest (31.2%) but significant vaccine efficacy 61 acid containing glycans per molecule. Although modern production technology provides 85 the means to express and purify properly folded recombinant glycoproteins at large 86 scale, controlling the glycosylation has been a persistent problem for most glycoproteins 87 due to the "non-templated" nature of glycosylation (30) (31) (32) . The final glycan structure of 88 proteins with only a few N-linked glycosylation sites can be highly variable with respect 89 to the glycan structure branching, saccharides present, sialic acid content, and net 90 charge. Glycosylation heterogeneity is known to result from a variety of variables 91 including: cell type, protein expression levels, cell culture conditions, monosaccharide 92 donor availability, and protein structure (30, (33) (34) (35) (36) . Controlling glycosylation 93 heterogeneity in gp120 is particularly problematic due to the fact that it contains an 94 average of 25 potential N-linked glycosylation sites (PNGS), comprising approximately 95 50% of the mass of the mature protein (37) (38) (39) (40) . Each glycan site may be different in 96 composition than others on the same molecule or different at the same position from 97 molecule to molecule. Variance is so great that 79 different glycan structures have been 98 found to occur a single position in envelope proteins expressed in normal CHO cells 99 (41). 100
In this paper we address the problems of glycosylation heterogeneity and bN-mAb 101 binding in the large-scale production of recombinant envelope proteins by the 102 development of a mutant CHO cell line (MGAT1 -CHO) in which the Mannosyl (Alpha-103 1,3-)-Glycoprotein Beta-1,2-N-Acetylglucosaminyltransferase (MGAT1) gene has been 104 inactivated using CRISPR/Cas9 gene editing. The nomenclature for MGAT1 gene has 105 changed over the years and was previously referred to as the GnTI gene. Inactivation 106 or deficiency of the MGAT1 limits N-linked glycosylation to early oligo-mannose glycans 107 (Man5-9) and enhances the binding of bN-mAbs to glycans dependent epitopes, as 108 compared to earlier gp120 vaccines produced in normal CHO cells. Although other 109 CHO cell lines , such as CHO Lec1, have been described that similarly limit 110 oligomannose-structures, they grow slowly, and differ from parental cell lines in 111 morphology and growth characteristics (42, 43 
Results

120
Silencing of CHO-S MGAT1 Gene
121
The goal of this project was to make an MGAT1 deficient CHO-S cell line using 122 CRIPSR/Cas9. With this gene knocked out, complex, sialic acid containing, glycans 123 cannot be formed and N-linked glycosylation is not processed beyond the oligomannose 124
Man5 structure (Fig. 1 ). The CRISPR/Cas9 gene editing system allows for specific 125 targeting of genes for deletion or modification by introducing double stranded breaks 126 (DSB) followed by non-homologous end joining (NHEJ) or homology directed repair 127 (HDR) (44, 45) . We utilized a CRISPR/Cas9 nuclease vector containing an OFP 128 reporter gene (Materials and Methods). After insertion of guide sequences, the vector 129 contained all of the elements needed to induce a double stranded break in the MGAT1 130 gene. The sequence of the CHO MGAT1 gene was identified from GenBank, gene ID: 131 100682529 (46). Three target specific double stranded guide sequences were ligated 132 into the vector between a U6 promoter and a tracrRNA sequence. The same vector 133 encodes the Cas9 endonuclease and an orange fluorescent protein reporter gene, 134 separated by a self-cleaving 2A peptide linker. This system allows for a single plasmid 135 to encode for both the Cas9 and a complete gRNA, enabling the use of non-Cas9 136 expressing cells. Following ligation of these guide sequences, the vectors were 137 transfected into CHO-S cells using the MaxCyte electroporation system (Fig. 2 ). Targets 138 1 and 2 were introduced individually; target 3 plasmid was mixed and added together in 139 equal ratio with target 2, creating three separate pools of transfected cells. Twenty-four 140 hours post transfection samples were serially diluted across five 96 well flat-bottoms 141 plates at a calculated density of 0.5 cells per well. The plates were examined daily, and 142 wells with more than a single colony was discarded. Across the 15 total plates, between 143 15 and 30 wells per plate contained single viable colonies that were transferred to 24 144 well plates upon reaching 20% confluency after 12 to 15 days. Wells in the 96 well 145 plates that did not have at least several dozen cells by day 15 were discarded. A total of 146 166 colonies were expanded to 24 well plates: 55 from target 1 pool, 67 from target 2 147 pool, and 44 from combined target 2/3 pool. Glc3Man9GlcNAc2 structure (left) to asparagine residues within the N-X-S/T motif of 152 nascent proteins. This initial structure is sequentially trimmed to Man9GlcNAc2 and then 153 Man5GlcNAc2 (center) as the protein moves from the ER to the Golgi apparatus. The plates, a 0.2mL aliquot was removed from each well and cells were tested for the ability 174 to bind fluorescein labeled Galanthus nivalis lectin (GNA). (E) GNA binding cells were 175 then expanded to shake flasks and cell lines were transiently transfected with a gene 176 encoding A244-rgp120. The cell culture supernatants were then collected after five days 177 and tested for binding of gp120 to the prototypic glycan dependent, broadly neutralizing 178 monoclonal antibody, PG9. (G) The gene encoding MGAT1 was sequenced from GNA 179 binding cell lines with that exhibited robust growth and the ability to secrete PG9 binding 180 gp120. The specific mutations induced by non-homologous end joining repair (NHEJR) 181
were determined by Sanger sequencing. 
Expression of gp120 in MGAT1 -CHO cell lines 212
Based on positive lectin binding criteria, the 14 candidate cell lines were grown in 213 125mL shake flasks ( Fig. 2) . Of those, the four fastest growing (3.4F10, 3.5D8, 3.5A2, 214 and 3.4D9) were utilized for transient transfection with a gene encoding gp120 from the 215 A244 strain of HIV-1 (A244-rgp120). Also transfected was the CHO-S parental cell line 216 for comparison. This gp120 A244 had the sequence point mutations E332N and N334S, 217 introducing a PNGS at N332. Five days post transfection the culture media was 218 harvested and secreted gp120 proteins were purified by immunoaffinity 219 chromatography. The purified products were assayed for protein yield, tested for identity 220 using immunoblot analysis (data not shown) and for the ability to bind the glycan 221 dependent bNAb, PG9 by fluorescent immune assay (FIA) (Fig. 4 ). Previous studies 222 have shown that this bNAb requires Man5 at position N160 in the V1/V2 domain for 223 binding (3). The results from this study confirmed that the MGAT1 -CHO cell lines could 224 bind this antibody whereas gp120 produced in the parental CHO-S cell line was unable 225 to bind PG9. From this analysis, a single MGAT1 -CHO cell line, 3.4F10, was selected 226 for further characterization and analysis ( Fig. 4) . 227
To be a viable substrate for biopharmaceutical production, the growth and protein yield 228 leaving the active extracellular domain intact. The diminished binding of gp120s 264 produced in the 3.5D9 and 3.5 A2 clones to PG9 suggest that partial MGAT1 activity 265 remains in these two clones compared to the 3.4F10 clone that, like gp120 produced in 266
GnTIcells, exhibits improved binding to PG9 (Figure 4) . Given that the single base 267 insertion in the 3.4F10 MGAT1 gene resulted in a frame shift 51 nucleotides into a 268 1276bp long gene, it is highly unlikely that the function of this gene could be restored by 269 random mutation. GnTIand MGAT1 -CHO cell lines was compared to the proteins produced in CHO-S 281 cell lines, we noted a reduction in mass of approximately 20kD. This is in keeping with 282 the smaller mass of the Man5 glycoform compared to that of the hybrid and complex 283 glycans found on CHO-S produced material. Following Endo H digestion, the protein 284 produced in the CHO-S cell line was largely unaltered, indicating that it possessed the 285 normal complex, sialic acid containing glycans. In contrast, the proteins produced in the 286 MGAT1 -CHO and HEK 293 GnTIcells were reduced to ~60kD in size. This result was 287 consistent with the observation that approximately half the mass of a given gp120 288 molecule can be attributed to N-linked glycosylation (47, 49, 50) . The complete 289 sensitivity of the proteins produced in the MGAT1 -CHO and HEK 293 GnTIcells to 290
Endo H digestion suggests that the glycosylation of these cell lines is exclusively high-291
mannose. When digested with PNGase F, all samples dropped to the same size, 292
confirming that undigested gp120 size variances were due to glycosylation differences. Additional studies were carried out to characterize the specific glycans 309 incorporated in the A244-rgp120 produced in the MGAT1 -CHO and the CHO-S cell 310 lines. Using MALDI-TOF-MS (Fig. 6 ), we found that 56.4% of the N-linked glycans 311 present on the MGAT1 -CHO produced gp120 were Man5, 19.2% were Man9, 11% were 312
Man8 and the remainder were Man6 and Man7. No complex sialic acid containing 313 glycans were detected ( Table 1 ). The degree of fucosylation was also significantly 314 lowered; fucosylation was only on Man5 glycoforms at the core GlcNAc and represented 315 3.16% of the total glycans present. 316
When the A244-rgp120 produced in CHO-S cells was examined, approximately 75% of 317 the glycans were complex or hybrid glycans and 25% represented the early 318 intermediates ranging from Man5 to Man9. No high mannose species were detected with 319 core GlcNAc fucose attached, but nearly all hybrid and complex glycans were Binding multiple bN-mAbs to gp120 expressed in the MGAT1 -336 CHO cells. 337 We next compared A244-rgp120 expressed in the MGAT1 -CHO cells with A244-338 rgp120 produced in normal CHO-S cells for the ability to bind bN-mAbs in a FIA. A 339 panel of prototypic bN-mAbs that recognize distinct sites of virus vulnerability in 340 monomeric and trimeric HIV envelope proteins were utilized (Fig. 7) . We noted a 341 significant improvement in the binding of PG9, CH01 and CH03 to the proteins 342 expressed in MGAT1 -CHO cells and HEK 293 GnTIcells compared to the CHO-S 343 cells. These bN-mAbs are known to bind to epitopes in the V1/V2 domain that require 344
Man5 at the N160 glycosylation site (3). Similarly we noted a significant improvement in 345 the binding of the PGT126 and PGT128 bN-mAbs that require oligo-mannose glycans 346 at the N301 and N332 glycosylation sites in the stem of the V3 domain (51). Mixed 347 results were seen for the PGT121 family of bN-mAbs where the binding to gp120 348 produced in both the MGAT1 -CHO and HEK 293 GnTIcells lines was lower than 349 binding of these antibodies to gp120 produced in the CHO-S cell line. In contrast, 350
binding to the 10-1074 bN-mAb, also in the PGT121 family, was unaffected by the 351 cellular substrate used for production. These results demonstrate that changing the 352 glycosylation, while leaving the amino acid sequence intact can significantly improve the 353 antigenic structure of A244-rgp120 with respect to the binding of several bNAbs to 
cells, CHO-S cells and HEK 293 GnTIcells. The binding of a panel of broadly 367
neutralizing monoclonal antibodies to purified A244-rgp120 produced in MGAT1 -CHO 368
cells, CHO-S cells, and HEK 293 GnTIcells was measured in a Fluorescence 369
Immunoassay (FIA). Briefly, purified proteins were captured onto wells of black 96 well 370 microtiter plates coated with a mouse monoclonal antibody against the N-terminal gD 371 tag present in all three proteins. Plates were then incubated with serial dilutions of bN-372 mAbs targeting: glycan-epitopes within the V1V2 domain (PG9, CHO1 and CHO3), the 373 glycan-epitopes within the V3 domain (PGT128, PGT126, PGT121, 10-1074 and 374 PGT122), or the CD4 binding site (VRC01). Plates were incubated with a 1:3,000 375 MVMc is a more recently identified strain(58) with little information available on its 393 binding to CHO or murine cells. Anything beyond noting the apparent dependence on 394 complex N-linked glycosylation would be speculative at this point. 395 396 were detected. The full list and procedure are described in the supplemental materials. 408
Discussion
409
A major goal in HIV vaccine research is to develop immunogens that elicit 410 bNAbs. The discovery that multiple bN-mAbs to HIV recognize glycan dependent 411 epitopes has altered our thinking of how best to produce this vaccine. Instead of using 412 standard CHO cell production cell lines, that incorporate complex and hybrid 413 glycosylation, a cell line that limits glycosylation to high-mannose forms may be useful 414 for gp120 immunogens. While we have long been able to produce properly folded Env 415 protein monomers (gp120 and gp140) as indicated by the ability to bind CD4 with high 416 affinity (59-63), until now we have not been able to replicate the glycan structures 417 required for the binding of multiple families of bN-mAbs in expression systems suitable 418 for large scale manufacturing. 419
The glycans that decorate the surface of native, virion-associated, HIV Env 420 protein are typically enriched for high-mannose variants, normally found on early 421 intermediate proteins within the ER and early Golgi (18, 19) . This unusual restriction in 422 glycan maturation is thought to be a consequence of steric hindrance occurring during 423 the formation of trimeric virus spike structures (64). Additionally, the high density of 424 PNGS that likely evolved as a glycan shield to prevent immune recognition of virus 425 sequences (38, 47, 65) appears to limit glycosidase and glycosyltransferase 426 modifications of Env glycans in the late ER and early Golgi Apparatus (GA) (18, 64) . 427
While expression of monomeric gp120 results in incorporation of complex glycosylation, 428 trimeric spike formation results in incomplete glycosylation and enrichment of virions 429 with high-mannose glycans (18, 19) . These differences in glycosylation might explain 430 the inability of previous HIV vaccines to elicit bNAbs to glycan dependent epitopes in 431 humans. However they don't explain the inability of previous vaccines to elicit bNAbs to 432 epitopes such as VRC01 that were present in most gp120 vaccines expressed in 433 normal CHO cells. Earlier vaccines such as the AIDSVAX B/E used in the RV144 trial 434 largely possessed complex sialic acid containing glycans and lacked the high-mannose 435 glycans required for a variety of bN-mAbs including PG9, CH01, CH03, PGT128, and 436 -1074 (16) . Although the level of protection achieved in the 16,000-person RV144 trial 437 was statistically significant (31.2%, P=0.04) this level was not sufficient for product 438 registration or clinical deployment. In this regard, the addition of one or more epitopes 439 recognized by bN-mAbs, such as the PG9 and PGT128 epitopes described in this 440 report, might improve the antigenic structure and immunogenicity of or recombinant 441 gp120 such that a level of protection of 50% or more, required for product approval is 442 achieved. Currently RV144 follow-up studies are in progress that make use of sialic acid 443 containing gp120 vaccine antigens, produced in normal CHO cells, like those used in 444 the original RV144 trial (66, 67). These new trials are trying to improve the level of 445 vaccine efficacy by prolonging the immunization schedule, altering the adjuvant 446 formulation, and replacing the canarypox vector co-administered with gp120 with 447 stronger, more virulent virus vectors. 448 intermediates, but are highly toxic and prohibitively expensive for large-scale 455 biopharmaceutical production (70, 71). Additionally, there exists evidence to suggest a 456 broad mannosidase inhibitor like kifunensine may negatively impact protein folding 457 through interference of the Calnexin/Calreticulin pathway (72-75). Glycosaminyl-458 transferase knockout cell lines from 293 HEK and CHO cells, referred to as HEK 293 459
10
GnTIand CHO Lec1, respectively, have previously been described. They were 460 generated through random ethyl methanesulfonate (EMS) mutagenesis, zinc finger 461 methods, or screened for modified glycosylation by resistance to cytotoxic lectin binding 462 (76-78). These lines lack a functional MGAT1 gene, responsible for the protein GnTI. 463
Knocking out the MGAT1 gene prevents processing of glycans beyond the 464
Man5GlcNAc2 stage, resulting in exclusively high-mannose glycoprotein production (28, 465 29). Such cell lines do not generally grow as robustly as their parental counterparts and 466 raise potential regulatory issues with potential uncharacterized genetic alterations. In 467 light of this, there is an unmet need for a cell line suitable for the scalable production of 468 HIV vaccine immunogens. We have addressed this problem by creating the novel 469 MGAT1 -CHO cell line described above. Our data suggests that this cell line possesses 470 several essential characteristics required for current Good Manufacturing Practices 471 (cGMP) such as robust growth in well defined serum free medium, the ability to grow to 472 high cell densities in suspension culture, a well defined mutation of the MGAT1 gene, 473 and freedom from contamination by adventitious agents. However, the ultimate utility of 474 this cell line will require characterization of stable cell lines with transfected envelope 475 proteins where the genetic stability of the transgene as well as the quality and yield of 476 the final product is determined. 477
Recombinant envelope proteins produced in the MGAT1 -CHO cell line, such as 478 the A244-rgp120 described in this report, can be used to test the hypothesis that 479 previous HIV vaccines such as the AIDSVAX B/E vaccine used in the RV144 trial (12-480 14) were ineffective because they lacked the glycan dependent epitopes required to 481 stimulate the formation of bN-mAbs. While the CHO MGAT1cell line provides a 482 practical way to produce envelope proteins with several glycan dependent epitopes 483 recognized by bNAbs not present on gp120s produced in normal CHO cell lines, we do 484 not yet know whether these epitopes will be immunogenic. Previous gp120 vaccine 485 trials such as RV144 failed to detect glycan independent VRC01-like antibodies even 486 though the VRC01 epitope was present on at least two different gp120s used for 487 immunization. Thus, some epitopes recognized by bNAbs are poorly immunogenic and 488 additional immunogenicity and formulation studies will likely be required to optimize 489 virus neutralizing antibody responses to the glycan epitopes of the type described in this 490 paper. Although the gp120 expression data presented here was derived exclusively 491 from small-scale transient transfection experiments, we anticipate that the cell line 492 described in this report will be useful for the development of stable MGAT1 -CHO cell 493 lines producing vaccines based on a variety of new concepts. These include guided 494 immunization to stimulate germline genes encoding bNAbs (79-81), Env proteins 495 designed with features that enhance antigen processing and presentation (82) as well 496 as glycopeptide scaffolds that enhance the immunogenicity of epitopes recognized by 497 bN-mAbs while eliminating non-protective immunodominant epitopes (21). Fisher, Life Technologies, Carlsbad, CA). HEK 293 GnTIsuspension adapted cells 503 were obtained from ATCC (ATCC, Manassas, VA). Stocks of suspension adapted CHO-504 S and HEK 293 GnTIcells were maintained in shake flasks (Corning, Corning, NY) 505 using a Kuhner ISF1-X shaker incubator (Kuhner, Birsfelden, Switzerland). For cell 506 propagation, shake flask cultures were maintained at 37°C, 8% CO2, and 125 rpm. 507
Static cultures were maintained in 96 or 24 well cell culture dishes and grown in a 508
Sanyo incubator (Sanyo, Moriguchi, Osaka, Japan) at 37°C and 8% CO2. 
CRISPR/Cas9 target design and plasmid preparation 536
We utilized a CRISPR/Cas9 nuclease vector with an OFP reporter (GeneArt, 537 Thermo Fischer Scientific, Waltham, MA) . Three target sequences to knock out the 538 CHO-S MGAT1 gene were designed using an online CRISPR RNA Configurator tool 539 (GE Dharmacon, Lafayette, CO). Target 1: CCCTGGAACTTGCGGTGGTC.Target 2: 540 GGGCATTCCAGCCCACAAAG. Target 3: GGCGGAACACCTCACGGGTG. Each 541 sequence was run in NCBI's BLAST tool for homologies with off-target sites in the CHO 542 genome. Single stranded DNA oligonucleotides and their complement strands were 543 synthesized (Eurofins Genomics, Louisville, KY) with extra bases on the 3' ends for 544 ligation into GeneArt CRISPR nuclease vector (Thermo Fisher, GeneArt, Waltham, MA) . 545
The strands were ligated and annealed into a GeneArt CRISPR vector using the 546 protocol and reagents supplied with the kit. One Shot® TOP10 Chemically Competent 547 E. coli were transformed and plated following the Invitrogen protocol (Thermo Fisher, 548 Invitrogen, Carlsbad, CA). These were incubated in 5mL LB broth at 37°C in a shaking 549 Cells were pelleted at 250g for 10 minutes, and then re-suspended in MaxCyte EP 560 buffer (MaxCyte Inc., Gaithersburg, MD) at a density of 2x10 8 cells/mL. Transfections 561 were carried out in the OC-400 processing assembly (MaxCyte Inc., Gaithersburg, MD) 562 with a total volume of 400µL and 8x10 7 total cells. CRISPR/Cas9 exonuclease with 563 guide sequence plasmid DNA suspended in endotoxin-free water was added to the cells 564 in EP buffer for a final concentration of 300µg of DNA/mL. The processing assemblies 565
were then transferred to the MaxCyte STX electroporation device and CHO protocol 566 was selected using the MaxCyte STX software. Following electroporation, the cells in 567 electroporation buffer were removed from the processing assembly and placed in 568 125mL Erlenmeyer cell culture shake flasks (Corning, Corning, NY) . The flasks were 569 placed into 37°C incubators with no agitation for 40 minutes. Following the rest period 570 pre-warmed OPTI-CHO media was added to the flasks for a final cell density of 4x10 6 571 cells/mL. Flasks were then moved to a Kuhner shaker and agitated at 125rpm. with warmed media to 10 cells/mL and added to five plates per pool in 50μL volumes. 580
Final calculated cell density was 0.5 cells/well in 100μL of media. Once any single-581 colony well reached ≈20% confluency, the contents were transferred to a 24 well cell 582 culture plate (Corning, Corning, NY) with 500uL of fresh media. When confluency 583 reached 50%, a 200μL aliquot was removed for testing via a GNA lectin-binding assay. 584
Following positive lectin binding, cells were moved to a 6 well cell culture plate (Corning, 585 Corning, NY) with 2mL of media per well. After 5 days of growth in 6 well plates the 586 GNA assay was repeated. Colonies exhibiting positive lectin binding were moved to 587 125mL shake flasks with an initial 6mL of media. Daily counts were taken and cell 588 cultures expanded to maintain 0.3x10 6 -1.0x10 6 cells/mL density. 589 experiments. The protein encoded by this gene was identical to that used to produce 609 the AIDSVAX B/E vaccine used in the RV144 trials (13, 14) with the exception that the 610 N-linked glycosylation site at N334 was moved to N332. For analytical scale 611 experiments, a total of 4x10 5 cells from each candidate MGAT1 -CHO line were placed 612 in 450µl of media in a 24 well cell culture plate. Fugene, 1.7µL, (Promega, Madison, WI) 613 was pre-incubated at room temperature for 30 minutes with 550ng of DNA in a total 614 volume of 50µL of media. Then 50µL of Fugene/DNA mixture was added to each well 615 for a final transfected volume of 500µL. Aliquots of supernatant were removed for assay 616 72 hours post transfection. 617
Lectin binding assay
For preparative scale transient transfection experiments, CHO cells were electroporated 618 following the above MaxCyte method. Twenty-four hours post electroporation, the 619 culture was supplemented with 1mM sodium butyrate (Thermo Fisher, Life 620
Technologies, Carlsbad, CA) and temperature lowered to 32°C. The cultures were fed 621 daily the equivalent of 3.5% of the original volume with Molecular Devices CHO A Feed 622 (Molecular Devices, Sunnyvale, CA), 0.5% Yeastolate (BD, Franklin Lakes, NJ), 2.5% 623 CHO-CD Efficient Feed A; and 0.25mM GlutaMax, 2 g/L Glucose (Sigma-Aldrich St. 624
Louis, MO). Cultures were run until cell viability dropped below 50%. Supernatant was 625 harvested by pelleting the cells at 250g for 30 minutes followed by pre-filtration through 626 Nalgene™ Glass Pre-filters (Thermo Scientific, Waltham, MA) and 0.45 micron SFCA 627 filtration (Nalgene, Thermo Scientific, Waltham, MA), then stored frozen at -20°C until 628 purification. Proteins were purified using an N-terminal affinity tag derived from type 1 629 herpes simplex virus glycoprotein D (gD) as previously described (16). 630
Glycosidase digestion and SDS-PAGE
631
Endo H and PNGase F (New England BioLabs, Ipswich, MA) digests were 632 performed per the manufacturer's protocol on 5ug of purified envelope protein using one 633 unit of glycosidase. Samples were reduced and denatured then digested overnight at 634 37°C. Digested samples were run on NuPAGE (Thermo Fisher, Invitrogen, Carlsbad, 635 CA) 4-12% BisTris precast gels in MES running buffer then stained with SimplyBlue 636 stain (Thermo Fisher, Invitrogen, Carlsbad, CA). 637
Fluorescence immunoassays to measure antibody binding 638 A fluorescence immunoassay (FIA) was used to measure the binding of 639 polyclonal or monoclonal antibodies to recombinant envelope proteins. For antibody 640 binding to purified proteins, Greiner Fluortrac 600 microtiter plates (Greiner Bio One, 641
Kremsmünster, Austria) were coated with 2ug/mL of purified envelope protein overnight 642 in PBS with shaking. Plates were blocked in PBS + 2.5% BSA (blocking buffer for 90 643 minutes, then washed four times with PBS containing 0.05% Tween-20 (Sigma). Serial 644 dilutions of monoclonal antibodies were added in a range from 10ug/mL to 645 0.0001ug/mL, and then incubated at 25 o C for 90 minutes with shaking. After incubation 646 and washing, 488 Alexa Fluor conjugated anti-human or anti-murine (Invitrogen, CA) 647 was added at a 1:3000 dilution in PBS + 1% BSA. Plates were incubated for 90 minutes 648 with shaking then washed four times with 0.05% Tween PBS using an automated plate 649 washer. Plates were then imaged in a plate spectrophotometer (Envision System, 650 Perkin Elmer) at excitation and emission wavelengths of 395nm and 490nm 651 respectively. For antibody binding to unpurified envelope proteins in cell culture 652 supernatants, Greiner Fluortrac 600 microtiter plates (Greiner Bio-one, Germany) were 653 coated with 2ug/mL of purified mouse monoclonal antibody to an epitope in the V2 654 domain (10C10) or the gD purification tag (34.1) overnight in PBS with shaking. Plates 655 were blocked in PBS + 2.5% BSA blocking buffer for 90 minutes, then washed four 656 times with PBS containing 0.05% Tween-20 (Sigma). 150µl of 40x diluted supernatant 657 were then added to each well or 10µg/mL of purified protein in control lanes, then 658 
